RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035

5/6/24 7:01:59 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $RDHL alert in real time by email

RedHill Biopharma Ltd. (NASDAQ:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the issue of a new Chinese patent Notice of Allowance covering opaganib[1] as a therapyg for inhibition of single-stranded RNA virus replication (notably Ebola Disease Virus) from the Chinese National Intellectual Property Administration (CNIPA), valid through 2035 (Chinese Patent Application No.: 202110229970.9 issued April 29, 2024).

Get the next $RDHL alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$RDHL

Date	Price Target	Rating	Analyst
9/15/2021	$23.00 → $21.00	Buy	HC Wainwright & Co.
8/31/2021	$22.00	Overweight	Cantor Fitzgerald

More analyst ratings

$RDHL
Press Releases

Fastest customizable press release news feed in the world

RedHill's Talicia® Adds 8 Million Lives With Coverage by Humana®'s Part D Plan. Also, New Data Supporting Simplified Three-Times Daily Talicia Dosing Published
Talicia is now covered by Humana's Part D Plan, providing access to Talicia for H. pylori therapy to more than eight million additional Medicare lives, without requiring prior therapeutic steps or authorization The recently updated American College of Gastroenterology (ACG) Clinical Guideline lists Talicia as a first-line option for treatment of H. pylori infection. Talicia continues to be the most prescribed branded H. pylori therapy by U.S. gastroenterologists Additionally, new data describing the foundations for Talicia's recent FDA-approved label change to a more convenient three-times daily (TID) "breakfast, lunch, and dinner" dosing routine, supporting patient adherence, has been publi
1/21/25 7:00:00 AM ET
$RDHL
Biotechnology: Pharmaceutical Preparations
Health Care
Radioprotective Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions Ongoing with U.S. Government on Advanced Development
Heightened geopolitical tensions and Homeland Security concerns call for the development of potential therapies that can be quickly and easily mobilized in the event of a mass casualty nuclear or radiological incident There are currently no known approved therapies for gastrointestinal acute radiation syndrome (GI-ARS) Positive results from new in vivo studies of opaganib as a treatment for GI-ARS, undertaken as part of the U.S. government's Radiation and Nuclear Countermeasures Program (RNCP) product pipeline development contract, further confirm opaganib's protective activity Discussions now ongoing with the National Institutes of Health's (NIH) National Institute of Allergy and Infectious
12/10/24 7:00:00 AM ET
$RDHL
Biotechnology: Pharmaceutical Preparations
Health Care
RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme Court
RedHill has been awarded a judgment of approximately $8 million plus costs in a summary judgment by the New York Supreme Court in its legal proceedings against Kukbo Co. Ltd The Court dismissed the entirety of Kukbo's counterclaims, ruling in favor of RedHill's demonstrated good faith commitment to the spirit and the letter of the agreements TEL-AVIV, Israel and RALEIGH, N.C., Dec. 2, 2024 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the Company has been awarded approximately $8 million (consisting of $6.5 million plus interest amounting to approximately $1.5 million), plus costs in a summary ju
12/2/24 7:00:00 AM ET
$RDHL
Biotechnology: Pharmaceutical Preparations
Health Care

RedHill Biopharma Announces Q1/22 Highlights: On Track for Positive Cash from Operations in H2/22
Targeting positive cash from operations to start during H2/22[1] Focus on earlier achievement of operational profitability thanks to a recently implemented comprehensive cost reduction plan, with expected operational cost savings of approximately $50 million over the next 18 months Continuous implementation of disciplined cost controls reduced Q1/22 cash used in operating activities by more than 70% to approximately $4 million, compared to approximately $15 million in Q4/21 Net revenues of $18.2 million in Q1/22; Cash balance[2] of $45 million as of March 31, 2022 Talicia® TRx up 12.8% over Q4/21 and Movantik® continues strong Q4/21 prescription performance Amendment improves key covenants i
6/23/22 7:00:00 AM ET
$RDHL
Biotechnology: Pharmaceutical Preparations
Health Care
RedHill Biopharma to Host First Quarter 2022 Financial Results and Operational Highlights Webcast on June 23, 2022
TEL AVIV, Israel and RALEIGH, N.C., June 17, 2022 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it will report its first quarter 2022 financial results and operational highlights on Thursday, June 23, 2022. The Company will host a conference call and webcast on Thursday, June 23, 2022, at 8:30 a.m. EDT, during which it will present key highlights for the first quarter of 2022. The webcast including slides will be broadcast live on the Company's website, https://ir.redhillbio.com/ev
6/17/22 8:30:00 AM ET
$RDHL
Biotechnology: Pharmaceutical Preparations
Health Care
RedHill Biopharma Reports Operational Highlights and Fourth Quarter & Full Year 2021 Financial Results
TEL AVIV, Israel and RALEIGH, N.C., March 17, 2022 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today reported its operational highlights and financial results for the fourth quarter and full year ended December 31, 2021. Dror Ben-Asher, RedHill's Chief Executive Officer, said: "In 2021, RedHill's team delivered record revenues against a pandemic backdrop, overall contribution of commercial operations to the company was positive for the first time in Q4/21 and positive late-stage clinical data for two novel oral COVID-19 drugs. A very strong fourth quarter for both Talicia® and Movantik®, coupled with disciplined c
3/17/22 7:59:00 AM ET
$RDHL
Biotechnology: Pharmaceutical Preparations
Health Care

RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035

Chat with this insight

Recent Analyst Ratings for
$RDHL

$RDHL
Press Releases

Fastest customizable press release news feed in the world

RedHill's Talicia® Adds 8 Million Lives With Coverage by Humana®'s Part D Plan. Also, New Data Supporting Simplified Three-Times Daily Talicia Dosing Published

Radioprotective Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions Ongoing with U.S. Government on Advanced Development

RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme Court

$RDHL
Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Redhill Biopharma Ltd.

SEC Form SC 13G filed by Redhill Biopharma Ltd.

SEC Form SC 13G filed by Redhill Biopharma Ltd.

$RDHL
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

HC Wainwright & Co. reiterated coverage on Redhill Biopharma with a new price target

Cantor Fitzgerald initiated coverage on Redhill Biopharma with a new price target

Redhill Biopharma downgraded by WBB Securities with a new price target

$RDHL
SEC Filings

$RDHL
Financials

Live finance-specific insights

SEC Form 6-K filed by Redhill Biopharma Ltd.

SEC Form 6-K filed by Redhill Biopharma Ltd.

SEC Form 424B5 filed by Redhill Biopharma Ltd.

RedHill Biopharma Announces Q1/22 Highlights: On Track for Positive Cash from Operations in H2/22

RedHill Biopharma to Host First Quarter 2022 Financial Results and Operational Highlights Webcast on June 23, 2022

RedHill Biopharma Reports Operational Highlights and Fourth Quarter & Full Year 2021 Financial Results

$RDHL
Leadership Updates

Live Leadership Updates

Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors

RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035

Chat with this insight

Recent Analyst Ratings for $RDHL

$RDHL Press Releases

Fastest customizable press release news feed in the world

RedHill's Talicia® Adds 8 Million Lives With Coverage by Humana®'s Part D Plan. Also, New Data Supporting Simplified Three-Times Daily Talicia Dosing Published

Radioprotective Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions Ongoing with U.S. Government on Advanced Development

RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme Court

$RDHL Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Redhill Biopharma Ltd.

SEC Form SC 13G filed by Redhill Biopharma Ltd.

SEC Form SC 13G filed by Redhill Biopharma Ltd.

$RDHL Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

HC Wainwright & Co. reiterated coverage on Redhill Biopharma with a new price target

Cantor Fitzgerald initiated coverage on Redhill Biopharma with a new price target

Redhill Biopharma downgraded by WBB Securities with a new price target

$RDHL SEC Filings

$RDHL Financials

Live finance-specific insights

SEC Form 6-K filed by Redhill Biopharma Ltd.

SEC Form 6-K filed by Redhill Biopharma Ltd.

SEC Form 424B5 filed by Redhill Biopharma Ltd.

RedHill Biopharma Announces Q1/22 Highlights: On Track for Positive Cash from Operations in H2/22

RedHill Biopharma to Host First Quarter 2022 Financial Results and Operational Highlights Webcast on June 23, 2022

RedHill Biopharma Reports Operational Highlights and Fourth Quarter & Full Year 2021 Financial Results

$RDHL Leadership Updates

Live Leadership Updates

Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors

Recent Analyst Ratings for
$RDHL

$RDHL
Press Releases

$RDHL
Large Ownership Changes

$RDHL
Analyst Ratings

$RDHL
SEC Filings

$RDHL
Financials

$RDHL
Leadership Updates